Nektar Therapeutics (NKTR) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

NKTR Nektar Therapeutics

Watchlist

0.9300
-0.0140-1.48%

Close Dec 31 16:00 ET

0.9620
+0.0320+3.44%

Post 17:26 ET

171.55MMarket Cap-1.11P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Insider Sale: Chief Legal Officer of $NKTR (NKTR) Sells 33,402 Shares
Quiver QuantitativeDec 26, 2024 19:15 ET
Don't Ignore The Insider Selling In Nektar Therapeutics
Simply Wall StDec 22, 2024 08:13 ET
Promising Future for Nektar Therapeutics: Innovative Approach in Autoimmune Disease Treatment With Rezpegaldesleukin
TipRanksDec 12, 2024 02:45 ET
Express News | Nektar Therapeutics : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $6.5
ReutersDec 10, 2024 06:06 ET
Nektar Therapeutics Announced NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients With Relapsed or Refractory Large B-cell Lymphoma At ASH Meeting; 73% Of NKTR-255 Treatment Group Vs 50% Of Placebo Group...
BenzingaDec 7, 2024 15:28 ET
Express News | Nektar Therapeutics Announces Nktr-255 Following Cd19-Directed CAR-T Therapy Enhanced Complete Response Rates in Patients With Relapsed or Refractory Large B-Cell Lymphoma at the 66TH Annual Ash Meeting
ReutersDec 7, 2024 12:00 ET

Comments

Teddy123

Dec 10, 2024 07:13

Recap: Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual AS

$Nektar Therapeutics (NKTR.US)$
08/12/2024 - 01:00
73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months
NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) 0-15 days post-administration being 5.8-fold...

This_Guy

Dec 8, 2024 17:28

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
Positive
73% complete response rate at 6 months vs 50% for placebo
5.8-fold improvement in CD8+ CAR-T cell kinetics compared to placebo
Two patients converted from partial to complete response with NKTR-255
Results exceeded historical benchmark data of 41-44% comple...

Trytosaveabit

Dec 8, 2024 15:46

Monday watch! PR/updated data released Saturday!

$Nektar Therapeutics (NKTR.US)$ Nektar Therapeutics Announced NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients With Relapsed or Refractory Large B-cell Lymphoma At ASH Meeting; 73% Of NKTR-255 Treatment Group Vs 50% Of Placebo Group Achieved Complete Response At 6 Months
Nektar Therapeutics (NASDAQ:NKTR) today announced results of its Phase 2 proof-of-concept study evaluating NKTR-255 as an adjuvant treatme...

Jaguar8

Nov 18, 2024 14:56

NEWS

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
Nektar Therapeutics (NKTR) presented preclinical data for NKTR-422, a novel modified CSF protein, at the 2024 ACR conference. The drug demonstrated promising results in inflammation resolution and tissue repair across multiple preclinical models. NKTR-422functions by targeting anti-inflammatory tissue resident macrop...

Teddy123

Nov 8, 2024 17:20

Nektar Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(8.7%)

$Nektar Therapeutics (NKTR.US)$
Target price $7

Heat List

Overall

No Data